SoftBank Reduces Stake in Vir Biotechnology

The transactions, made under a 10b5-1 trading plan, signal continued adjustments in SoftBank’s biotech holdings.

October 14, 2025

SoftBank offloads over 538,000 shares across two days

SoftBank has trimmed its position in Vir Biotechnology. Through its affiliate, SVF Endurance (Cayman) Ltd, the firm sold over 538,000 shares across two days in October 2025. These sales were made under a Rule 10b5-1 trading plan put in place on September 3, allowing for scheduled transactions that comply with regulatory safeguards around insider trading.

The first block of shares— 72,133 —was sold on October 7 at an average price of $5.60. The next day, another 466,242 shares were sold at a weighted average of $6.05. All transactions were completed across a range of execution prices, and detailed price-level breakdowns are available upon request to the SEC or shareholders.

SVF Endurance now holds just over 15.6 million shares in Vir. That stake remains substantial, but the recent activity reflects a recalibration of exposure.

Ownership structure and oversight

Structurally, the shares are held by SVF Endurance, a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. Oversight of the Vision Fund sits with SB Investment Advisers (UK) Limited, which is authorized and regulated in the UK. SBIA UK manages all investment decisions, including when and how positions like this one are adjusted.

Details on the transaction and what it signals

There were no derivative securities involved in this filing—only sales of common stock. The reporting parties disclosed that the transactions were consistent with their plan and did not involve any new acquisitions or exercises.

For market participants watching ownership changes in the biotech space, this update provides clear visibility into how one of the sector’s largest investors is managing its stake. Vir Biotechnology remains a core holding for SoftBank, but this move shows that the firm is actively tuning its exposure in response to internal strategy or market conditions.

All signatures were filed on October 9, confirming the transaction details across SVF Endurance, SoftBank Vision Fund, and SB Investment Advisers.